GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies	Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm	Recruiting	Phase 1 / Phase 2	2026-09-18		NCT06948981

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Grit Biotechnology	19
Institute of Hematology & Blood Diseases Hospital, China	285

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences	Tianjin	China	6

Clinical trials